BioCentury | May 31, 2010
Finance

Performance Counts

...$41.0 $126.0 Biology: vitamin D3 analogs and TREM (Triggering Receptor Expressed on Myeloid cells) receptors G2M...
BioCentury | Mar 19, 2007
Company News

Topotarget, Novartis deal

...Zemab to treat cancer. The option was granted in a 2003 deal between NVS and G2M...
BioCentury | Jul 25, 2005
Strategy

European takeouts

...it didn't already own; Evotec Neuro had E20M ($24.1M) in cash Mar TopoTarget (CSE:TOPO) Denmark G2M...
BioCentury | May 16, 2005
Finance

IPO angst in Europe

...of Baceca to treat skin cancer. It gained the compound through its acquisition of Germany's G2M...
BioCentury | Mar 14, 2005
Strategy

TopoTarget adds mass

...II Prevent severe tissue damage following accidental extravasation of chemotherapeutics Ph II/III (Launch '06) TopoTarget BACECA/G2M-777...
...deacetylase (HDAC) inhibitor Inflammatory skin diseases Ph II (Ph II in skin cancer in '05) G2M...
...completed G2M Topotect plus etoposide Catalytic inhibitor of topoisomerase II Brain metastasis Ph I TopoTarget PEAC/G2M-777...
BioCentury | Mar 7, 2005
Company News

TopoTarget, G2M Cancer Drugs AG deal

...G2M for an undisclosed sum. G2M's PEAC (Pulse Enhanced Acetylation) formulation of the HDAC inhibitor G2M-777...
...with an inflammatory skin disease and will begin Phase II in skin cancer this year. G2M...
...compound is partnered with CuraGen Corp. (CRGN, New Haven, Conn.). TopoTarget A/S , Copenhagen, Denmark G2M...
BioCentury | Mar 2, 2005
Company News

TopoTarget acquires G2M

...Germany) for an undisclosed sum. G2M's PEAC (Pulse Enhanced Acetylation) formulation of the HDAC inhibitor G2M-777...
...with an inflammatory skin disease and will begin Phase II in skin cancer this year. G2M...
BioCentury | Jun 28, 2004
Product Development

HDAC attack

...Hormone-refractory prostate cancer (HRPC) Merck SAHA Hydroxamic acid Ph II Cutaneous T cell lymphoma (CTCL) G2M...
BioCentury | Jun 28, 2004
Product Development

Similar, but not the same

...and safety also may vary depending on how many of the isoforms a compound targets. G2M...
...acid to treat colon cancer and leukemia. According to CEO Thomas Borcholte, the PEAC formulation, G2M-777...
BioCentury | May 10, 2004
Emerging Company Profile

G2M: Loosening the ground

...Inc. (MRK, Whitehouse Station, N. J.) in February (see BioCentury, March 1). G2M's lead product, G2M-777...
...selected tumor indication. G2M-777 is a marketed compound in an undisclosed non-cancer indication. Two of G2M's...
...of patients. G2M's other HDAC inhibitors - G2M-701, G2M-702 and G2M-707 - were developed using G2M's...
Items per page:
1 - 10 of 12
BioCentury | May 31, 2010
Finance

Performance Counts

...$41.0 $126.0 Biology: vitamin D3 analogs and TREM (Triggering Receptor Expressed on Myeloid cells) receptors G2M...
BioCentury | Mar 19, 2007
Company News

Topotarget, Novartis deal

...Zemab to treat cancer. The option was granted in a 2003 deal between NVS and G2M...
BioCentury | Jul 25, 2005
Strategy

European takeouts

...it didn't already own; Evotec Neuro had E20M ($24.1M) in cash Mar TopoTarget (CSE:TOPO) Denmark G2M...
BioCentury | May 16, 2005
Finance

IPO angst in Europe

...of Baceca to treat skin cancer. It gained the compound through its acquisition of Germany's G2M...
BioCentury | Mar 14, 2005
Strategy

TopoTarget adds mass

...II Prevent severe tissue damage following accidental extravasation of chemotherapeutics Ph II/III (Launch '06) TopoTarget BACECA/G2M-777...
...deacetylase (HDAC) inhibitor Inflammatory skin diseases Ph II (Ph II in skin cancer in '05) G2M...
...completed G2M Topotect plus etoposide Catalytic inhibitor of topoisomerase II Brain metastasis Ph I TopoTarget PEAC/G2M-777...
BioCentury | Mar 7, 2005
Company News

TopoTarget, G2M Cancer Drugs AG deal

...G2M for an undisclosed sum. G2M's PEAC (Pulse Enhanced Acetylation) formulation of the HDAC inhibitor G2M-777...
...with an inflammatory skin disease and will begin Phase II in skin cancer this year. G2M...
...compound is partnered with CuraGen Corp. (CRGN, New Haven, Conn.). TopoTarget A/S , Copenhagen, Denmark G2M...
BioCentury | Mar 2, 2005
Company News

TopoTarget acquires G2M

...Germany) for an undisclosed sum. G2M's PEAC (Pulse Enhanced Acetylation) formulation of the HDAC inhibitor G2M-777...
...with an inflammatory skin disease and will begin Phase II in skin cancer this year. G2M...
BioCentury | Jun 28, 2004
Product Development

HDAC attack

...Hormone-refractory prostate cancer (HRPC) Merck SAHA Hydroxamic acid Ph II Cutaneous T cell lymphoma (CTCL) G2M...
BioCentury | Jun 28, 2004
Product Development

Similar, but not the same

...and safety also may vary depending on how many of the isoforms a compound targets. G2M...
...acid to treat colon cancer and leukemia. According to CEO Thomas Borcholte, the PEAC formulation, G2M-777...
BioCentury | May 10, 2004
Emerging Company Profile

G2M: Loosening the ground

...Inc. (MRK, Whitehouse Station, N. J.) in February (see BioCentury, March 1). G2M's lead product, G2M-777...
...selected tumor indication. G2M-777 is a marketed compound in an undisclosed non-cancer indication. Two of G2M's...
...of patients. G2M's other HDAC inhibitors - G2M-701, G2M-702 and G2M-707 - were developed using G2M's...
Items per page:
1 - 10 of 12